{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:45:48Z","timestamp":1766515548011,"version":"3.40.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04688-0","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T14:03:02Z","timestamp":1679580182000},"page":"7453-7459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-8485","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Arrabal Polo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2060","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"Melgarejo Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-0890","authenticated-orcid":false,"given":"Yaiza","family":"Y\u00e1\u00f1ez Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Morales Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Pareja V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-1811","authenticated-orcid":false,"given":"Miguel","family":"Arrabal Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"issue":"6","key":"4688_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJH Arends","year":"2016","unstructured":"Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69(6):1046\u20131052","journal-title":"Eur Urol"},{"issue":"1","key":"4688_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G et al (2014) Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65(1):69\u201376","journal-title":"Eur Urol"},{"issue":"1","key":"4688_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000052419","volume":"39","author":"R Colombo","year":"2001","unstructured":"Colombo R, Brausi M, Da Pozzo L, Salonia A, Montorsi F, Scattoni V et al (2001) Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication a pilot study on marker lesion. Eur Urol 39(1):95\u2013100","journal-title":"Eur Urol"},{"issue":"23","key":"4688_CR4","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","volume":"21","author":"R Colombo","year":"2003","unstructured":"Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21(23):4270\u20134276","journal-title":"J Clin Oncol"},{"issue":"6","key":"4688_CR5","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2011","unstructured":"Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D (2011) Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107(6):912\u2013918","journal-title":"BJU Int"},{"unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017;155. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf","key":"4688_CR6"},{"issue":"3","key":"4688_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","volume":"27","author":"SM Di Stasi","year":"2009","unstructured":"Di Stasi SM, Riedl C (2009) Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 27(3):325\u2013330","journal-title":"World J Urol"},{"issue":"3","key":"4688_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170(3):777\u2013782","journal-title":"J Urol"},{"key":"4688_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","volume":"40","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos F, Gonz\u00e1lez-Padilla DA, Gonz\u00e1lez-D\u00edaz A, de la Rosa-Kehrmann F, Rodr\u00edguez-Antol\u00edn A, Inman BA et al (2022) Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol 40:999\u20131004","journal-title":"World J Urol"},{"issue":"2","key":"4688_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"3","key":"4688_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63(3):462\u2013472","journal-title":"Eur Urol"},{"issue":"5","key":"4688_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"A Ojea","year":"2007","unstructured":"Ojea A, Nogueira JL, Solsona E, Flores N, G\u00f3mez JMF, Molina JR et al (2007) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus calmette-guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C. Eur Urol 52(5):1398\u20131406","journal-title":"Eur Urol"},{"issue":"21","key":"4688_CR13","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.3390\/jcm10215105","volume":"10","author":"A Plata","year":"2021","unstructured":"Plata A, Guerrero-Ramos F, Garcia C, Gonz\u00e1lez-D\u00edaz A, Gonzalez-Valc\u00e1rcel I, de la Morena JM et al (2021) Long-term experience with hyperthermic chemotherapy (HIVEC) using Mitomycin-C in patients with non-muscle invasive bladder cancer in Spain. J Clin Med 10(21):5105","journal-title":"J Clin Med"},{"issue":"1","key":"4688_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF (2018) ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u2018BCG failure\u2019 non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer 18(1):1224","journal-title":"BMC Cancer"},{"key":"4688_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011935.pub2\/full","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B, Draeger DL, Krabbe LM, Dersch R et al (2020) Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011935.pub2\/full","journal-title":"Cochrane Database Syst Rev"},{"key":"4688_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001023","author":"V Sharma","year":"2020","unstructured":"Sharma V, Wymer KM, Borah BJ, Saigal CS, Litwin MS, Packiam VT et al (2020) Cost-effectiveness of maintenance bacillus Calmette-Gu\u00e9rin for intermediate and high risk Nonmuscle invasive bladder cancer. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000001023","journal-title":"J Urol"},{"issue":"4","key":"4688_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","volume":"32","author":"A Sousa","year":"2016","unstructured":"Sousa A, Pi\u00f1eiro I, Rodr\u00edguez S, Aparici V, Monserrat V, Neira P et al (2016) Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate\u2013high-risk non-muscle-invasive bladder cancer. Int J Hyperth 32(4):374\u2013380","journal-title":"Int J Hyperth"},{"issue":"4","key":"4688_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, Turturica D, Bauerov\u00e1 L, Bruins HM et al (2021) European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 79(4):480\u2013488","journal-title":"Eur Urol"},{"issue":"11","key":"4688_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","volume":"15","author":"WS Tan","year":"2018","unstructured":"Tan WS, Kelly JD (2018) Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol 15(11):667\u2013685","journal-title":"Nat Rev Urol"},{"issue":"1","key":"4688_CR20","first-page":"63","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L, Devall AJ, Loubi\u00e8re LS, Pope AM et al (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus calmette-gu\u00e9rin therapy (HYMN): a phase III, open-label. Randomised Controlled Trial Eur Urol 75(1):63\u201371","journal-title":"Randomised Controlled Trial Eur Urol"},{"issue":"22","key":"4688_CR21","first-page":"02552","volume":"S0302\u20132838","author":"WS Tan","year":"2022","unstructured":"Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P et al (2022) adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a Phase 2, open-label. Randomised Controlled Trial Eur Urol S0302\u20132838(22):02552","journal-title":"Randomised Controlled Trial Eur Urol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04688-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:39:09Z","timestamp":1744213149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04688-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4688"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04688-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"5 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study obtained the approval of the Local Ethics Committee before experiment was started (Approved 27\/7\/2018. IRB number 0992-N-18).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the manuscript and images.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}